CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00111-1	**95**	**1.4%**	Epigenetic gene regulation during the differentiation of human embryonic stem cells: Impact on neural repair	$631,569	$2,516,613
RC1-00346-1	**90**	**2.9%**	Derivation of Inhibitory Nerve Cells from Human Embryonic Stem Cells	$592,418	$2,507,223
RC1-00115-1	**89**	**4.3%**	Molecular and Cellular Transitions from ES Cells to Mature Functioning Human Neurons	$702,744	$2,879,210
RC1-00354-1	**89**	**5.7%**	Prospective isolation of hESC-derived hematopoietic and cardiomyocyte stem cells	$656,901	$2,636,900
RC1-00113-1	**88**	**7.1%**	Constructing a fate map of the human embryo	$613,181	$2,532,388
RC1-00359-1	**87**	**8.6%**	An in vitro and in vivo comparison among three different human hepatic stem cell populations.	$626,153	$2,504,614
RC1-00353-1	**87**	**10.0%**	The Dangers of Mitochondrial DNA Heteroplasmy in Stem Cells Created by Therapeutic Cloning	$632,499	$2,530,000
RC1-00132-1	**85**	**11.4%**	Chemical Genetic Approach to Production of hESC-derived Cardiomyocytes	$759,000	$3,036,002
RC1-00116-1	**85**	**12.9%**	USING HUMAN EMBRYONIC STEM CELLS TO UNDERSTAND AND TO DEVELOP NEW THERAPIES FOR ALZHEIMER'S DISEASE	$628,688	$2,512,664

CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00110-1	**85**	**14.3%**	Improved hES Cell Growth and Differentiation	$628,138	$2,509,438
RC1-00100-1	**84**	**15.7%**	Functional Genomic Analysis of Chemically Defined Human Embryonic Stem Cells	$656,900	$2,628,635
RC1-00119-1	**84**	**17.1%**	Generation of inner ear sensory cells from human ES cells toward a cure for deafness	$591,812	$2,469,373
RC1-00131-1	**83**	**18.6%**	Spinal ischemic paraplegia: modulation by human embryonic stem cell implant.	$563,687	$2,445,716
RC1-00104-1	**83**	**20.0%**	Modeling Myocardial Therapy with Human Embryonic Stem Cells	$531,888	$2,229,140
RC1-00148-1	**81**	**21.4%**	Mechanisms to maintain the self-renewal and genetic stability of human embryonic stem cells	$642,500	$2,570,000
RC1-00137-1	**79**	**22.9%**	Human oocyte development for genetic, pharmacological and reprogramming applications	$596,068	$2,469,104
RC1-00347-1	**79**	**24.3%**	Understanding hESC-based Hematopoiesis for Therapeutic Benefit	$639,601	$2,566,702
RC1-00124-1	**79**	**25.7%**	Embryonic Stem Cell-Derived Therapies Targeting Cardiac Ischemic Disease	$620,676	$2,524,617
RC1-00134-1	**79**	**27.1%**	Immunology of neural stem cell fate and function	$612,775	$2,501,125

CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00125-1	**78**	**28.6%**	MEF2C-Directed Neurogenesis From Human Embryonic Stem Cells	$758,999	$3,035,996
RC1-00123-1	**77**	**30.0%**	Establishment Of Stem Cell Lines From Somatic Cell Nuclear Transfer-Embryos in Humans	$637,534	$2,556,066
RC1-00133-1	**75**	**31.4%**	Guiding the developmental program of human embryonic stem cells by isolated Wnt factors	$551,371	$2,354,820
RC1-00135-1	**75**	**32.9%**	Human stem cell derived oligodendrocytes for treatment of stroke and MS	$639,601	$2,566,701
RC1-00151-1	**75**	**34.3%**	Engineering a Cardiovascular Tissue Graft from Human Embryonic Stem Cells	$641,472	$2,618,704
RC1-00149-1	**73**	**35.7%**	Human Embryonic Stem Cell Therapeutic Strategies to Target HIV Disease	$629,208	$2,516,831
RC1-00142-1	**72**	**37.1%**	microRNA Regulation of Cardiomyocyte Differentiation from Human Embryonic Stem Cells	$791,000	$3,164,000
RC1-00108-1	**69**	**38.6%**	Regulated Expansion of Lympho-hematopoietic Stem and Progenitor Cells from Human Embryonic Stem Cells (hESC)	$614,094	$2,551,088
RC1-00345-1	**66**	**40.0%**	hESC-Derived Motor Neurons For the Treatment of Cervical Spinal Cord Injury	$578,418	$2,396,932

CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00144-1	**66**	**41.4%**	Preclinical Model for Labeling, Transplant, and In Vivo Imaging of Differentiated Human Embryonic Stem Cells	$539,500	$2,257,040
RC1-00107-1	**69**	**42.9%**	Controlling Stem Cell Differentiation with GPCR Signals	$782,729	$3,130,921
RC1-00356-1	**68**	**44.3%**	ABILITY OF HUMAN ES CELL-DERIVED NEURAL PRECURSORS TO CONTRIBUTE TO AND REPAIR DAMAGED NEURAL CIRCUITS	$640,685	$2,562,741
RC1-00145-1	**65**	**45.7%**	Control Mechanisms Governing Human ESC Self Renewal and Differentiation	$630,001	$2,507,692
RC1-00114-1	**64**	**47.1%**	hES Differentiation in Lesch Nyhan Disease	$494,490	$1,987,915
RC1-00102-1	**64**	**48.6%**	Generation and functional genomic characterization of human embryonic stem cell-derived progenitor cells.	$524,630	$2,094,929
RC1-00152-1	**64**	**50.0%**	Dopaminergic Differentiation of Human Embryonic Stem Cells	$690,472	$2,937,237
RC1-00101-1	**---**	**51.4%**	IN VIVO REGENERATIVE POTENTIAL OF hESC-DERIVED SKELETAL MYOBLASTS	---	---
RC1-00103-1	**---**	**52.9%**	Factors Regulating Stemness in Human Embryonic Stem Cells	---	---

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00105-1	---	**54.3%**	Creating a Human Tumor Micro-environment with Embryonic Stem Cells	---	---
RC1-00106-1	---	**55.7%**	Generating Reprogrammed Pluripotent Human Cell Lines Using a Histone Modification Barcode	---	---
RC1-00109-1	---	**57.1%**	Chemical and Functional Genomic Approaches toward Understanding hESCs	---	---
RC1-00112-1	---	**58.6%**	Intracellular signaling mechanism for control of hESC pluripotency	---	---
RC1-00117-1	---	**60.0%**	Interaction between transplanted human embryonic stem cell-derived neuronal precursors and endogenous neurogenesis in ischemic brain	---	---
RC1-00120-1	---	**61.4%**	Genome-wide analysis of hormonal systems important for human embryonic stem cell derivation	---	---
RC1-00121-1	---	**62.9%**	Human Embryonic Stem Cell Therapy for Myocardial Infarction	---	---
RC1-00122-1	---	**64.3%**	Genetic Modification of Human Embryonic Stem Cells	---	---
RC1-00126-1	---	**65.7%**	Constructing a library of custom-tailored human embryonic stem cell-derived cardiomyocytes for specific heart therapies	---	---

CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00127-1	---	**67.1%**	Effect of growth factors on hES cell derivation, growth, and genomic stability	---	---
RC1-00128-1	---	**68.6%**	Control of human Embryonic Stem Cell Pluripotence and Fate Choice	---	---
RC1-00129-1	---	**70.0%**	Mechanisms of Human Embryonic Stem Cell Self-Renewal	---	---
RC1-00130-1	---	**71.4%**	Monitored Systemic Delivery Of HESC to Pathological Organs	---	---
RC1-00136-1	---	**72.9%**	Human Embryonic Stem Cell Survival and Transformation	---	---
RC1-00138-1	---	**74.3%**	Studying Chromosomal Aneuploidy During Human Embryogenesis Using Human Embryonic Stem Cells Derived From Embryos Characterized by Preimplantation Genetic Diagnosis	---	---
RC1-00139-1	---	**75.7%**	Investigation of the mechanism that initiates the molecular heterogeneity in human embryonic stem cells	---	---
RC1-00140-1	---	**77.1%**	Derivation and Characterization of hESCs Derived from Single Cleavage-Stage Blastomeres	---	---
RC1-00141-1	---	**78.6%**	Functional characterization of the pivotal role of a novel zinc finger protein ZNF206 in regulating early lineage allocation & commitment	---	---

CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00146-1	---	**80.0%**	Endoderm-specific integration for human embryonic stem cells: towards tissue regenerative solutions for lung and pancreas	---	---
RC1-00147-1	---	**81.4%**	DESIGN AND ENGINEERING OF NEURAL STEM CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS FOR REGENERATION AND REPAIR OF MULTIPLE SCLEROSIS	---	---
RC1-00337-1	---	**82.9%**	Generation of hNSC lines from hESC: Effect of selective derivation and transplantation niche on cell fate decisions and recovery after SCI	---	---
RC1-00338-1	---	**84.3%**	Converting Human Embryonic Stem Cells to Dopamine Neurons for Parkinson's Disease	---	---
RC1-00339-1	---	**85.7%**	Human Embryonic Stem Cells for Incurable Skin Diseases and Chronic Wounds	---	---
RC1-00340-1	---	**87.1%**	Engineering human embryonic stem cells into ectodermal organs	---	---
RC1-00341-1	---	**88.6%**	Building an HIV Resistant Immune System Using Pluripotent Stem Cells	---	---
RC1-00343-1	---	**90.0%**	Quantitative time-lapse analysis of pluripotency and trophectoderm differentiation at the single-cell level	---	---
RC1-00344-1	---	**91.4%**	Matrix-Assisted hESC Transplantation for Myocardium Stabilization	---	---

CIRM COMPREHENSIVE – RFA 06-02

Recommended for funding = ☐ Recommended for funding if funds available = ☐ Not recommended (NR) for funding at this time = ☐

Application#	Avg	Cumulative Percentile	Application Title	Requested Budget, Year 1	Requested Budget, Total
RC1-00349-1	---	**92.9%**	Embryonic Stem Cell-Derived Hemangioblasts for Hematopoietic Stem Cell Reconstitution	---	---
RC1-00350-1	---	**94.3%**	Human Embryonic Stem Cell for Myocardial Restoration	---	---
RC1-00351-1	---	**95.7%**	Cryopreservation of Embryonic Progenitors Derived from Human Embryonic Stem Cells	---	---
RC1-00358-1	---	**97.1%**	Embryonic stem cell-derived neural stem cells for brain tumor and ALS therapy.	---	---
RC1-00459-1	---	**98.6%**	Imaging Human ES-Derived Cells: Defining Parameters for Safety in Regenerative Medicine.	---	---
RC1-00478-1	---	**100.0%**	Regulation of Self Renewal and Lineage Commitment in Human Embryonic Stem Cells	---	---